Published in Rare Dis on February 23, 2015
Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors. Drug Des Devel Ther (2016) 0.80
Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy. EBioMedicine (2017) 0.78
Dystrophin: The dead calm of a dogma. Rare Dis (2016) 0.77
Proteomic profiling of mdx-4cv serum reveals highly elevated levels of the inflammation-induced plasma marker haptoglobin in muscular dystrophy. Int J Mol Med (2017) 0.75
Alternative activation of macrophages. Nat Rev Immunol (2003) 27.53
Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol (2009) 8.65
X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A (1984) 8.35
The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol (2008) 6.56
Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med (2011) 6.02
Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med (2010) 4.28
Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol (2010) 4.21
Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev (2008) 3.54
Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol (2010) 3.44
A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J Cell Biol (2001) 3.41
Virus-specific CD4(+) memory-phenotype T cells are abundant in unexposed adults. Immunity (2013) 3.38
Deconstructing the peptide-MHC specificity of T cell recognition. Cell (2014) 3.24
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev (2008) 3.18
Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol (2014) 3.12
A special population of regulatory T cells potentiates muscle repair. Cell (2013) 3.09
Interleukin-6 is an essential regulator of satellite cell-mediated skeletal muscle hypertrophy. Cell Metab (2008) 3.00
Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest (2007) 2.99
Muscle-specific expression of insulin-like growth factor I counters muscle decline in mdx mice. J Cell Biol (2002) 2.76
First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4+CD25+CD127- T regulatory cells. Clin Immunol (2009) 2.71
Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol (1984) 2.66
Pathophysiology of duchenne muscular dystrophy: current hypotheses. Pediatr Neurol (2007) 2.62
Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum Mol Genet (2008) 2.27
DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. Dev Cell (2011) 2.17
Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest (2009) 2.10
Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle. Clin Immunol (2001) 1.94
B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol (2012) 1.80
Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest (1996) 1.67
Interleukin-10 reduces the pathology of mdx muscular dystrophy by deactivating M1 macrophages and modulating macrophage phenotype. Hum Mol Genet (2010) 1.59
Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice. Neuromuscul Disord (2006) 1.57
TNF-alpha regulates myogenesis and muscle regeneration by activating p38 MAPK. Am J Physiol Cell Physiol (2006) 1.55
Administration of CD4+CD25highCD127- regulatory T cells preserves β-cell function in type 1 diabetes in children. Diabetes Care (2012) 1.52
T regulatory cells in autoimmune diabetes: past challenges, future prospects. J Clin Immunol (2008) 1.52
Differences in angiogenic potential of classically vs alternatively activated macrophages. Immunobiology (1997) 1.44
Do immune cells promote the pathology of dystrophin-deficient myopathies? Neuromuscul Disord (2001) 1.43
T-cell-dependent fibrosis in the mdx dystrophic mouse. Lab Invest (2000) 1.38
Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol (2010) 1.36
Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword? FEBS J (2013) 1.33
Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs. J Clin Invest (2012) 1.27
Specific T cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy. J Immunol (1994) 1.23
Muscle undergoes atrophy in association with increase of lysosomal cathepsin activity in interleukin-6 transgenic mouse. Biochem Biophys Res Commun (1995) 1.21
T and B lymphocyte depletion has a marked effect on the fibrosis of dystrophic skeletal muscles in the scid/mdx mouse. J Pathol (2007) 1.16
CD8(+) T cells in facioscapulohumeral muscular dystrophy patients with inflammatory features at muscle MRI. J Clin Immunol (2010) 1.16
Eosinophilia of dystrophin-deficient muscle is promoted by perforin-mediated cytotoxicity by T cell effectors. Am J Pathol (2000) 1.11
Prednisolone decreases cellular adhesion molecules required for inflammatory cell infiltration in dystrophin-deficient skeletal muscle. Neuromuscul Disord (2004) 1.11
Major basic protein-1 promotes fibrosis of dystrophic muscle and attenuates the cellular immune response in muscular dystrophy. Hum Mol Genet (2008) 1.11
Tumor necrosis factor-alpha inhibition of skeletal muscle regeneration is mediated by a caspase-dependent stem cell response. Stem Cells (2008) 1.10
Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Sci Transl Med (2014) 1.09
The T-cell receptor repertoire of regulatory T cells. Immunology (2008) 1.09
Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment. Neuromuscul Disord (2008) 1.09
Redefinition of dystrophin isoform distribution in mouse tissue by RT-PCR implies role in nonmuscle manifestations of duchenne muscular dystrophy. Mol Genet Metab (1998) 1.06
Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther (2013) 1.06
IFN-γ promotes muscle damage in the mdx mouse model of Duchenne muscular dystrophy by suppressing M2 macrophage activation and inhibiting muscle cell proliferation. J Immunol (2011) 1.04
Interleukin 35: a key mediator of suppression and the propagation of infectious tolerance. Front Immunol (2013) 1.03
Srf-dependent paracrine signals produced by myofibers control satellite cell-mediated skeletal muscle hypertrophy. Cell Metab (2012) 1.00
Evaluation of dystrophic dog pathology by fat-suppressed T2-weighted imaging. Muscle Nerve (2009) 0.98
IL-2 therapy in type 1 diabetes: "Trials" and tribulations. Clin Immunol (2013) 0.97
IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab. Ann Rheum Dis (2014) 0.96
Shared signaling systems in myeloid cell-mediated muscle regeneration. Development (2014) 0.95
In vivo expansion of regulatory T cells with IL-2/IL-2 mAb complexes prevents anti-factor VIII immune responses in hemophilia A mice treated with factor VIII plasmid-mediated gene therapy. Mol Ther (2011) 0.94
Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol (2014) 0.93
The future of uveitis treatment. Ophthalmology (2013) 0.92
Cytokines and chemokines as regulators of skeletal muscle inflammation: presenting the case of Duchenne muscular dystrophy. Mediators Inflamm (2013) 0.91
IL-6 signaling blockade increases inflammation but does not affect muscle function in the mdx mouse. BMC Musculoskelet Disord (2012) 0.91
State of the art. Four easy pieces: interconnections between tissue injury, intermediary metabolism, autoimmunity, and chronic degeneration. Proc Am Thorac Soc (2006) 0.88
Long-term administration of the TNF blocking drug Remicade (cV1q) to mdx mice reduces skeletal and cardiac muscle fibrosis, but negatively impacts cardiac function. Neuromuscul Disord (2014) 0.86
Inflammation in muscular dystrophy and the beneficial effects of non-steroidal anti-inflammatory drugs. Muscle Nerve (2012) 0.85
Fibrosis and inflammation are greater in muscles of beta-sarcoglycan-null mouse than mdx mouse. Cell Tissue Res (2014) 0.85
The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies. Int J Exp Pathol (2006) 0.80
A comparative study of N-glycolylneuraminic acid (Neu5Gc) and cytotoxic T cell (CT) carbohydrate expression in normal and dystrophin-deficient dog and human skeletal muscle. PLoS One (2014) 0.78
Anti-interleukin-6 receptor antibody (MR16-1) promotes muscle regeneration via modulation of gene expressions in infiltrated macrophages. Biochim Biophys Acta (2014) 0.78
Autoimmunity, recessive diseases, and gene replacement therapy. Mol Ther (2010) 0.78
Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses. Muscle Nerve Suppl (1995) 0.77